The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients

Recently, proton pump inhibitor (PPI) intake has been linked to acute kidney injury and chronic kidney disease. The objective of this study was to assess the effect of PPIs on renal function and rejection rate in kidney transplant patients. We performed a single center, retrospective analysis of 455...

Verfasser: Flothow, Dominik J. G.
Suwelack, Barbara
Pavenstädt, Hermann-Joseph
Schütte-Nütgen, Katharina
Reuter, Stefan Johannes
FB/Einrichtung:FB 05: Medizinische Fakultät
Dokumenttypen:Artikel
Medientypen:Text
Erscheinungsdatum:2020
Publikation in MIAMI:30.06.2021
Datum der letzten Änderung:30.06.2021
Angaben zur Ausgabe:[Electronic ed.]
Quelle:Journal of Clinical Medicine 9 (2020) 1, 258, 1-13
Schlagwörter:proton pump inhibitor; kidney transplantation; transplant rejection; GFR
Fachgebiet (DDC):610: Medizin und Gesundheit
Lizenz:CC BY 4.0
Sprache:English
Förderung:Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF-Dokument
URN:urn:nbn:de:hbz:6-17029744356
Weitere Identifikatoren:DOI: 10.3390/jcm9010258
Permalink:https://nbn-resolving.de/urn:nbn:de:hbz:6-17029744356
Verwandte Dokumente:
Onlinezugriff:10.3390_jcm9010258.pdf
10.3390_jcm9010258_supplement.pdf
Daten herunterladen:ZIP-Datei

Recently, proton pump inhibitor (PPI) intake has been linked to acute kidney injury and chronic kidney disease. The objective of this study was to assess the effect of PPIs on renal function and rejection rate in kidney transplant patients. We performed a single center, retrospective analysis of 455 patients who received a kidney transplant between May 2010 and July 2015. Median follow-up time was 3.3 years. PPI prescription was assessed in half-year intervals. Primary outcome parameters were the estimated glomerular filtration rate (eGFR), change in the eGFR, and >30% and >50% eGFR decline for different time periods (up to four years post-transplantation). Our secondary outcome parameter was occurrence of biopsy proven acute rejection (BPAR) in the first two years after transplantation. Except for >30% eGFR decline from half a year to two years post-transplantation (p = 0.044) and change in the eGFR, >30% and >50% eGFR decline showed no association with PPI intake in our patient cohort (p > 0.05). Similarly, by analyzing 158 rejection episodes, BPAR showed no correspondence with mean daily PPI intake. We conclude that prolonged PPI intake has no relevant adverse effect on kidney transplant function or rejection rates. Polypharmacy, however, remains a problem in renal transplant recipients and it is thus advisable to question the necessity of PPI prescriptions when clear indications are missing.